Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study A systematic review of ...
Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in The ...
Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...
Treatment for multiple myeloma has evolved significantly, with long-term survival increasingly within reach for many patients. Achieving optimal outcomes requires not only addressing symptoms but also ...
Daratumumab plus VRd and frontline daratumumab plus VTd produced deep, durable responses in patients with transplant-eligible multiple myeloma in updates to the PERSEUS and CASSIOPEIA trials, ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignancies with Optical Genome Mapping (OGM).
Multiple myeloma is a cancer of plasma cells, the antibody-making white blood cells that live in your bone marrow. When these cells turn abnormal and multiply, they crowd out healthy blood-forming ...
The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results